Peking Union Medical College Hospital
Beijing, China
Location status: Recruiting
NCT Number: NCT07387952
Chronic constipation is a common gastrointestinal disease with a global prevalence of about 15%, significantly affecting daily life and quality of life. Traditional treatments primarily rely on laxatives, which may lead to adverse effects with prolonged use, while surgical interventions have limited patient acceptance. Recent studies indicate that gut microbiota therapies-including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT)-can effectively manage chronic constipation. This study aims to investigate the safety and efficacy of FMT combined with a prebiotic nutritional intervention (using a co-localization strategy) in the treatment of functional constipation. Additionally, the investigators will explore changes in fecal microbiota and metabolomic profiles following the treatment.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Not applicable
Beijing, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In this group, colonoscopy is performed and a colostomy is placed in the ileocecal region. Bacterial infusion is performed for 3 days with 100ml graft per day. Within 30 minutes after receiving the microbiota transplantation, take the high dietary fiber preparation and dissolve it in water according to the instructions. Blood, stool, and colonoscopy-derived mucosal samples are collected before and after FMT and Researchers conduct follow-ups.
Other names: FMT with nutritional intervention
Time frame: Baseline, Weeks 4, 8, 12, 18, and 24
The number of Spontaneous Bowel Movements (SBM) per week recorded by the participant in a diary.
Time frame: Baseline, Weeks 4, 8, 12, 18, and 24
Stool consistency is evaluated using the Bristol Stool Form Scale. The scale ranges from Type 1 (Separate hard lumps) to Type 7 (Liquid consistency). Type 1 and 2 indicate constipation, while Type 3 and 4 are considered normal. Higher scores indicate looser stool consistency.
Time frame: Baseline, Weeks 4, 8, 12, 18, and 24
Patient-reported assessment of the effort required to defecate. Participants rate their straining severity on a scale (e.g., from 0 to 3, where 0 represents no straining and 3 represents severe straining). Higher scores indicate worse symptoms.
Time frame: From baseline through Week 24
Number of participants with adverse events. Assessment includes monitoring for specific gastrointestinal symptoms (e.g., aggravation of diarrhea, abdominal discomfort/bloating) and systemic infections (e.g., secondary intestinal infection, bacteremia). Safety is assessed via telephone and offline visits.
Time frame: Baseline, Weeks 2, 4, 8, 12, 18, and 24
Fecal samples are collected to analyze the changes in the gut microbiota structure. Analysis includes the relative abundance of bacterial species and diversity indices (e.g., Shannon index) using Metastats analysis to compare pre- and post-treatment compositions.
Contact information is provided by the study sponsor or research team.
Peking Union Medical College Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07386795
Chronic Constipation, Constipation - Functional
Beijing, China
View Trial DetailsNCT07213856
Basal Ganglia Diseases, Brain Diseases
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT07126327
Behavior, Behavioral Symptoms
Aarhus, Gotland, Denmark
View Trial DetailsNCT07519915
Colonic Diseases, Congenital Abnormalities
Erlangen, Germany
View Trial Details